[1] Beiki O,Hall P,Ekbom A,et al.Breast canacer incidence and case fatality among 4.7 million women in relation to social and ethnic background:a population-based cohort study［J］.Breast Cancer Res,2012,14(1):R5.
[2] Stevens KN,Vachon CM,Lee AM,et al.Common breast cancer susceptibility loci are associated with triple negative breast cancer［J］.Cancer Res,2011,71(19):6240-6249.
[3] Zhou SL,Yang WT.Advance of clinicopathological and molecular research of triple negative breast cancer［J］.China Oncology,2013,23(8):603-608.［周淑玲，杨文涛.三阴性乳腺癌的临床病理特征及分子研究进展［J］.中国癌症杂志，2013,23(8）：603-608.］
[4] Piao SM,Piao LZ.Advance of molecular targeted therapy research of triple negative breast cancer［J］.China Maternity and Child Care,2011,26(30):4787-4789.［朴素庙，朴龙镇.“三阴性”乳腺癌分子靶向治疗的研究进展［J］.中国妇幼保健，2011,26（30）：4787-4789.］
[5] Zhang JJ.Effects of PARP-1 inhibitors on the growth activity and cisplatin resistance of the ovarian cancer C13 cells［D］.Jinan:Shandong University,2012.［张敬敬.PARP-1抑制剂对卵巢癌耐药细胞C13生长活性及耐药性的影响［D］.济南：山东大学,2012.］
[6] William Jacot,Simon Thezenas.BRCA1 promoter hypermethylation,53BP1 protein expression and PARP1 activity as biomarker of DNA repair deficit in breast cancer［J］.BMC Cancer,2013,13:523:1-11.
[7] Yao C,Zhang JG.The correlation study of p53 and PARP1 expression and clinical pathological characteristics of triple- negative breast cancer patients［J］.J Nantong University(Medical Sciences)2014，34(6)：507-508.［姚婵，章建国.三阴性乳腺癌患者PARP1和p53表达及临床病理特点的相关性研究［J］.南通大学学报（医学版），2014,34（6）：507-508.］
[8] Li YS,Li ZY,Li L,et al.The expression PARP1 and p53 in triple- negative breast cancer and its clinical significance［J］.Modern Oncology,2014,22（1）：70-74.［李严锁，李占勇,李蕾，等.PARP-1和p53在三阴性乳腺癌中表达的相关性及临床意义［J］.现代肿瘤医学,2014,22（1）：70-74.］
[9] Li HL,Li SZ，Zhai LL,et al.Expression and significance of PARP1 and PAR in triple-negative breast cancer［J］.Chin J Clin Oncol 2014,41（24）：1564-1567.［李慧兰，李帅翟,翟丽丽，等.PARP1及其活性产物PAR在三阴性乳腺癌中的表达及意义［J］.中国肿瘤临床，2014,41（24）：1564-1567.］
[10] Wang RR,Liu X,Lu S,et al.The expression of BAG-1,EGFR and PARP-1 in breast cancer and evaluate the clinical significance［J］.Chin J Clin Oncol,2014,41(13)：866-871.［王荣荣，刘晓,陆苏，等.乳腺癌中BAG-1 EGFR和PARP-1 的表达及其临床意义［J］.中国肿瘤临床，2014,41（13）：866-871.］
[11] William D，Foulkes.Triple negative breast cancer［J］.N Eng J Med,2010,363(20):1938-1948.
[12] Yuan ZY,Wang SS,Gao Y,et al.The clinical features and prognosis factor analysis in 305 cases triple-negative breast cancer［J］.Cancer,2008,27（6）：561-565.［袁中玉，王树森，高岩,等.305例三阴性乳腺癌患者的临床特征及预后因素分析［J］.癌症，2008,27（6）：561-565.］
[13] Zhang CJ.Multi-disciplinary collaboration in the process of diagnosis and treatment breast cancer［J］.Medicine and Philosophy(Clinical Decision Making Forum Edition),2009,30(8):4-9.［张超杰.乳腺癌诊治过程中的多学科协作［J］.医学与哲学：临床决策论坛版，2009,30（8）：4-9.］
[14] Yuan YW,Sun ZJ.The latest treatment and research progress of triple-negative breast cancer［J］.Chongqing Medical,2015,44（16）：2279-2282.［袁业伟,孙治君.三阴性乳腺癌最新治疗及研究进展［J］.重庆医学,2015,44（16）：2279-2282.］
[15] Zhang YJ.The relationship between the expression of CerbB-2,Ki-67,PARP-1 before and after neoadjuvant chemotherapy in breast cancer and response to neoadjuvant chemotherapy［D］.Kunming:Kunming Medical University,2012.［张一君.乳腺癌患者新辅助化疗前后C-erbB-2、Ki-67、PARP-1的表达与化疗疗效的关系［D］.昆明：昆明医科大学，2012.］
[16] Chen TB.The expression of Kif4A,PARP-1 and p53 in breast cancer tissue and clinicopathological significance［D］.Suzhou:Suzhou University,2013.［陈铜兵.乳腺癌组织中Kif4A、PARP-1、p53蛋白的表达及其临床病理学意义［D］.苏州：苏州大学，2013.］
[17] Yu Lei,Yang Qing,Bi Fangfang.Expression and significance of poly ADP-ribose polymerase-1 in endometrial carcinoma［J］.Modern Oncology,2013,21(4):849-852.［于蕾,杨清,毕芳芳.PARP-1在子宫内膜样腺癌中的表达［J］.现代肿瘤医学，2013,21(4):849-852.］